About UstekinumabUstekinumab is a new, human monoclonal antibody with a novel mechanism of action, the p40 subunit of cytokine IL – 12 is targets, and interleukin-23 , naturally occurring proteins, which are important for the regulation of probably are probably associated with several immunoregulatory mediated inflammatory diseases, including plaque psoriasis. Ustekinumab is under regulatory review in the United States.
2 Langley RG, Lebwohl M, Efficacy and safety of ustekinumab, a human monoclonal antibody interleukin-12/23 in patients with psoriasis: 52-week results from a randomized, double – blind, placebo – controlled trial . The Lancet. 2008; 371:1675-84. International Federation of Psoriasis Associations. Profile of psoriasis. Available at: Accessed on 10 November 2008.She said that each year cervical 500,000 affect women, and the life of of a quarter million women. Women in poor countries most affected, , therefore, had the cervical cancer deaths result of the extremely defined availability of screening of and treating. Added: ‘ added: ‘If the reflection of of the main advancements in women’s health in the coming years, vaccine against HPV is of the great breakthroughs of the great breakthroughs , it is urgent that governments beginning in the world prioritizing cervical using sustainability. Political and financial commitments.